RespireRx Pharmaceuticals Inc (fka RSPI)

[K-G]

gfp927z,
I'll need to review Dr. Stoll's statements also, but I think your assessment is too pessimistic. I thought he implied that for both back-up compounds they did not see a similar cellular toxicity response as with CX-717. I interpret this to mean that they conducted similar dosing level studies (probably in rats)with theses compounds. Perhaps I missed something, and was just looking for something positive...